title: Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
authors.forename: N
authors.initials: N
authors.lastname: Deguchi
authors.forename: T
authors.initials: T
authors.lastname: Kawamura
authors.forename: A
authors.initials: A
authors.lastname: Shimizu
authors.forename: R
authors.initials: R
authors.lastname: Kitamura
authors.forename: M
authors.initials: M
authors.lastname: Yanagi
authors.forename: N
authors.initials: N
authors.lastname: Shibagaki
authors.forename: H
authors.initials: H
authors.lastname: Matsue
authors.forename: S
authors.initials: S
authors.lastname: Shimada
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate